中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2008年
12期
1026-1029
,共4页
伊曲康唑多中心临床研究工作组
伊麯康唑多中心臨床研究工作組
이곡강서다중심림상연구공작조
血液病%真菌病%伊曲康唑
血液病%真菌病%伊麯康唑
혈액병%진균병%이곡강서
Hematologic diseases%Mycoses%Itraconazole
目的 观察伊曲康唑静脉注射液/口服液序贯治疗血液系统疾病患者侵袭性真菌感染(IFI)的疗效及安全性.方法 所有血液系统疾病住院患者,符合IFI的诊断标准,后者类型包括确诊IFI、临床诊断IFI、拟诊IFI.本研究为开放研究,疗程为4~6周,分静脉给药阶段和口服给药阶段.静脉给药共14d,最初2d剂量为400mg/d,分两次给药,给药间隔12h;其后12d,剂量为200ms/d,1次/d.静脉用药结束后,继续给受试者序贯伊曲康唑口服液维持治疗,推荐剂量400mg/d,分两次给药(200 mg,2次/d),共用2~4周.根据受试者的病情决定每1~2周进行疗效与安伞性评价.结果 227例入组患者治疗结束后有效率为75.33%,其巾痊愈率达47.14%;227例患者治疗后205例退热(90.3%),中位退热时间5 d(2~20 d);可评价的186例患者,真菌学清除率为69.89%.发生与药物相关的不良事件11例,无与药物相关的严重不良事件发生.结论 伊曲康唑静脉注射液/口服液序贯治疗血液系统疾病患者IFI的疗效可靠,应用安全.
目的 觀察伊麯康唑靜脈註射液/口服液序貫治療血液繫統疾病患者侵襲性真菌感染(IFI)的療效及安全性.方法 所有血液繫統疾病住院患者,符閤IFI的診斷標準,後者類型包括確診IFI、臨床診斷IFI、擬診IFI.本研究為開放研究,療程為4~6週,分靜脈給藥階段和口服給藥階段.靜脈給藥共14d,最初2d劑量為400mg/d,分兩次給藥,給藥間隔12h;其後12d,劑量為200ms/d,1次/d.靜脈用藥結束後,繼續給受試者序貫伊麯康唑口服液維持治療,推薦劑量400mg/d,分兩次給藥(200 mg,2次/d),共用2~4週.根據受試者的病情決定每1~2週進行療效與安傘性評價.結果 227例入組患者治療結束後有效率為75.33%,其巾痊愈率達47.14%;227例患者治療後205例退熱(90.3%),中位退熱時間5 d(2~20 d);可評價的186例患者,真菌學清除率為69.89%.髮生與藥物相關的不良事件11例,無與藥物相關的嚴重不良事件髮生.結論 伊麯康唑靜脈註射液/口服液序貫治療血液繫統疾病患者IFI的療效可靠,應用安全.
목적 관찰이곡강서정맥주사액/구복액서관치료혈액계통질병환자침습성진균감염(IFI)적료효급안전성.방법 소유혈액계통질병주원환자,부합IFI적진단표준,후자류형포괄학진IFI、림상진단IFI、의진IFI.본연구위개방연구,료정위4~6주,분정맥급약계단화구복급약계단.정맥급약공14d,최초2d제량위400mg/d,분량차급약,급약간격12h;기후12d,제량위200ms/d,1차/d.정맥용약결속후,계속급수시자서관이곡강서구복액유지치료,추천제량400mg/d,분량차급약(200 mg,2차/d),공용2~4주.근거수시자적병정결정매1~2주진행료효여안산성평개.결과 227례입조환자치료결속후유효솔위75.33%,기건전유솔체47.14%;227례환자치료후205례퇴열(90.3%),중위퇴열시간5 d(2~20 d);가평개적186례환자,진균학청제솔위69.89%.발생여약물상관적불량사건11례,무여약물상관적엄중불량사건발생.결론 이곡강서정맥주사액/구복액서관치료혈액계통질병환자IFI적료효가고,응용안전.
Objective We performed this study to investigate the efficacy and safety of sequential jntravenous and oral itraconazole in the treatment of invasive fungal infection(IFI)in the patients with hematological diseases.Methods AII the patients fit for the diagnostic criteria of IFI(proven diagnosis.probable diagnosis and possible diagnosis)with hematological diseases were entered into this studv.The trial Was designed as an open labeled,multi-centered study.with the total treatment duration of 4-6 weeks including intravenous and oral period.Intravenous itraconazole was given at the dose of 200 rag.twice a day in the first two days,and adjusted to 200 mg/d for subsequent 12 days.Sequential oral itraconazole was given at the dose of 200 mg,twice a day,for 2-4 weeks for maintenance therapy.Efficacy and safety evaluation was performed every 1-2 weeks according to the physician's decision.Results Two hundred and twenty seven patients were enrolled into this study.The overall response rate was 75.33%and the cure rate was 47.14%.Two hundred and five patients(205/227.90.3%)defervesced after a median of 5 days (2-20 days).One hundred and eishty six patients were applicable for microbiological evaluation.among them.69.89%responded to the treatment.Eleven treatment-related adverse events occurred during the study and none of them were severe adverse events.Conclusion Sequential intravenous and oral itraconazole therapy was effective for IFI and tolerated well in patients with hematological diseages.